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EFFECT OF WIRELESS GLUCOSE METER ON HYPERGLYCEMIA AND 
PRENATAL VISITS 
 CHENIN VERONICA POELS 
ABSTRACT 
 Gestational diabetes mellitus can have devastating effects in the health of the 
mother and child. While pregnancy rates are decreasing, prevalence of GDM is 
increasing, and it is estimated that up to 9% of pregnancies are complicated by diabetes in 
the United States. Traditional treatment and monitoring of gestational diabetes mellitus 
relies on patient’s compliance to document glycemic levels. This proposed study will 
evaluate the effectiveness of telemedicine using a wireless glucose meter that transmits 
information to the providers in real time. The prospective open cohort randomized 
clinical trial will take place in medical centers around Boston. Two hundred participants 
diagnosed with gestational diabetes will be recruited over a period of 24 months from 
these centers and randomly placed into two groups. One group will follow traditional 
treatment, and the intervention group will be asked to use iGlucose meter system. 
Glycemic levels and frequency of prenatal visits will be evaluated and analyzed. If 
telemedicine proves to be efficacious in treating GDM, this would give providers a new 
treatment plan to consider to effectively manage blood glucose levels and reduce poor 
perinatal outcomes related to gestational diabetes mellitus. 
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INTRODUCTION 
Background 
Gestational diabetes mellitus (GDM) is a condition that develops during pregnancy, in 
which the woman develops carbohydrate intolerance, similar to existing diabetes mellitus 
(DM). It is estimated that up to 9% of pregnancies are complicated by diabetes, with most 
of the glucose intolerance having been exacerbated during pregnancy. Women with GDM 
have a higher risk of complications prior to delivery and during, including preeclampsia 
and having to undergo a C-section. Maternal risks after delivery also include 
development of DM, while fetal risks include macrosomia (also risk for mother), neonatal 
hypoglycemia, hyperbilirubinemia, shoulder dystocia and birth trauma.  
In 2014, the U.S. Preventive Services Task Force recommended that all pregnant 
patients be screened for GDM at 24 weeks of gestational age. Screening includes a 50mg 
oral glucose tolerance test (OGTT), and a 1-hour venous glucose determination for 
patients with low suspicion of pre-existing diabetes. If a patient is suspected of having 
pre-existing diabetes or metabolic syndrome (overweight with BMI >25 or 23 in Asian 
Americans, increased abdominal girth, family history of DM, previous GDM, 
hypertension, polycystic ovarian syndrome, cardiovascular disease), early pregnancy 
screening includes a fasting blood glucose followed by a 75mg glucose load 2-hr plasma 
glucose measurement. A more widely accepted approach, called the two-step approach, 
discards the use of a 75mg glucose solution and substitutes it with an initial oral glucose 
challenge test of 50mg followed by a 100mg oral glucose tolerance test where blood 
glucose levels are checked 1 hr, 2hrs and 3hrs after ingestion of oral solution. The oral 
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glucose tolerance test (OGTT) is only performed if the patient screened positive with the 
50mg oral glucose solution, reducing the need to subject patients to this test. Screening 
thresholds differ by institutions, with special consideration regarding patient population 
and individual patient. 
Treating GDM can significantly reduce the rate of newborn complications, 
mentioned earlier, and development of preeclampsia. The frequency of C-sections is also 
reduced when GDM is well controlled. Treatment is not limited to just medications, but 
dietary counseling and physical exercise encouragement are the primary treatments of 
GDM. Women who are diagnosed with GDM should be counseled about nutrition and 
exercise before prescribing them insulin or metformin.  
There exist various different types of classification of GDM. Type A, which is 
diabetes that originated during pregnancy, is further divided into two subtypes. Type 
A1GDM individuals are patients whose GDM is diet-controlled and usually tend to have 
less pregnancy and delivery negative outcomes than A2GDM individuals. Type A2GDM 
is the class assigned to patients who are unable to control their glycemic levels with diet 
or exercise and require insulin treatment. Type B to T, are types of pre-gestational 
diabetes that existed prior to pregnancy. 
Statement of the Problem 
Recommended monitoring of GDM is much more intensive than for non-pregnant 
patients with DM; daily glucose monitoring four times a day, once after waking up 
(fasting) and the rest after each meal. Monitoring schedule and treatment might vary, 
depending if the patient has elevated blood sugars at a certain time of day but normal 
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throughout of the day. Clinics will prescribe or provide a glucometer which stores the last 
week’s blood glucose values, and is reviewed on the next prenatal visit. Adjustments of 
the medication or monitoring can be made if needed, and the next visit is scheduled. 
However, having to present to the prenatal clinic frequently might be tedious to some 
patients, especially to patients who do not have access to transportation, have children at 
home to take care of, or cannot afford to take one day off work per week.  
With new technology emerging, implementing technology in medicine is key in 
this time and age. Phone applications have evolved to transfer data and improve quality 
of life, either by setting reminders or easing communication with recipients who are 
across the city, state or country. Incorporating health phone applications will enable 
patients’ access to providers and vice versa. Data entered into an app can be viewed by 
the health providers in real time, and through secure app messaging the providers/nurses 
can readjust medication or inform the patient to come in for their weekly visit.  
Hypothesis 
The use of telemedicine in gestational diabetes will improve control of hyperglycemia 
(pre-prandial blood glucose goal levels under 100 mg/dL and 1-hour post-prandial blood 
glucose goal under 150mg/dL) and reduce frequency of prenatal visits compared to 
traditional treatment.  
Objectives and specific aims 
As part of monitoring gestational diabetes mellitus in real time using telemedicine, 
patients will be able to receive instantaneous notifications about their glucose level. 
Providers will interact with the patient, and provide care early enough, therefore 
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hyperglycemia will be regulated and acted upon. The aim of the study is to determine the 
impact of iGlucose system meters to decrease blood sugar levels in pregnant women 
diagnosed with GDM and the impact on the frequency of prenatal visits related to glucose 
monitoring.  
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REVIEW OF THE LITERATURE 
Definition of Gestational Diabetes Mellitus 
Gestational diabetes mellitus (GDM) is a condition defined as impaired glucose tolerance 
or hyperglycemia with onset during pregnancy.1 During early gestation, metabolic 
changes stimulate adipose tissue accumulation, therefore insulin secretion increases and 
insulin sensitivity may change or remain the same. However, later in gestation, adipose 
tissue deposits decrease, while post-prandial free fatty acids increase, and glucose 
disposal mediated by insulin decreases by 40 to 60% compared to pre-gravid levels, 
inducing increased hepatic glucose production and severe insulin resistance.2 3 Insulin 
secretion increases up to 200% in order to maintain euglycemic levels in the normal 
pregnant mother 2 4 and pre-metabolic syndrome may exacerbate these conditions. 
Elevated adiposity correlates with the secretion of adipokines, pro-inflammatory 
cytokines from adipose tissue. 5 These include leptin, TNF-alpha, adiponectin, 
interleukin-6 and others.6  
Adiponectin, a protein involved in glucose regulation by stimulating skeletal 
muscle glucose uptake by reducing hepatic gluconeogenesis and FFA breakdown, has 
been shown to be decreased in patients with GDM vs non-GDM patients. 7 This protein is 
exclusively synthesized in adipocytes and follows an inverse relationship with higher 
body mass index (BMI), type 2 DM 8, fasting c-peptide concentrations (marker of insulin 
secretion) and progression of gestation- even in lean women.7 9 Adiponectin is further 
reduced by TNF-alpha and other pro-inflammatory mediators, by inhibition of 
adiponectin transcription in adipocytes.10 Once a patient has been diagnosed with GDM, 
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she is at higher risk of developing GDM in her next pregnancy due to lower plasma 
adiponectin concentrations post pregnancy.11 These patients are also at higher risk of 
developing peripheral vascular dysfunction and have lower stroke volume and cardiac 
output compared to non-GDM patients when adjusting for BMI.12 Lipolysis is accelerated 
in pregnancy likely in response to placental growth hormone, and exaggerated in obese or 
GDM patients. Reduction in the transcription factor peroxisome proliferator-activated 
receptor (PPAR-γ1, expressed in all tissues- regulates fatty acid storage and glucose 
metabolism), due to TNF-alpha13 and growth hormone14, inhibits adipocyte 
differentiation leading to an excess response of lipolysis and adipose tissue insulin 
resistance in pregnancy.15 Another mechanism associated with insulin resistance is 
related to human placental lactogen (hPL)16 and human placental growth hormone 
(hPGH)17. In pregnancy both hormones are increased; hPL induces insulin secretion from 
the pancreas18, and hPGH has been documented to cause severe peripheral insulin 
resistance when overexpressed in transgenic mice19 and increase expression of the p85 
subunit of phosphatidylinositol 3-kinase (PI3K, involved in metabolic actions of insulin) 
acting as an inhibitor of PI3K activity therefore triggering severe insulin resistance in 
skeletal muscle.20 21 
Consequently, increased pro-inflammatory cytokines, decreased adiponectin, 
additional lipolysis, placental growth hormone among other metabolic changes trigger 
general insulin resistance and initiate GDM. 
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Epidemiology 
Approximately 9% of all pregnancies in the United States are affected by GDM, which 
results in 200,000 cases annually.1.A recent study showed that GDM prevalence varies 
depending on risk factors across different racial or ethnic groups. Advanced maternal age 
(older than 35 years), obesity, family history of type 2 diabetes (T2DM), and foreign-
born status affect each ethnic group differently. Advanced maternal age has little impact 
on Asian Indians compared to Hispanics and non-Hispanic whites, but the Asian Indian 
group carries the highest prevalence out of nine ethnic groups observed.22 The same study 
also showed that overweight or obesity is the most significant risk factor for non-
Hispanic whites, Hispanics, Filipinos and Asian Indians. The percentage of GDM cases 
that are attributed to overweight and obesity among Hispanics is 39.1%, 41.2% for non-
Hispanic whites, 50.45% for non-Hispanic blacks and up to 52.8% among American 
Indians while Asian Indians only have a 15.1% prevalence attributable to obesity.23  
As in T2DM, Asians in general may be more susceptible to insulin resistance 
which may be due to a dissimilar distribution of lipid stores compared to other ethnicities 
and Asian’s greater body fat percentages given lower BMI levels.24 A study review 
concluded that the prevalence of GDM in a population echoes the prevalence of T2DM in 
the same population,25 with the women of childbearing age belonging to a minority being 
disproportionately affected by obesity and T2DM.26 27  
Low maternal educational level has been associated with GDM as well, after 
adjusted for race, age, parity and family history of diabetes. This is likely due to higher 
proportions of overweight and obesity among this population. Bouthoorn et al found that 
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low educational level is associated with a threefold risk of developing GDM in 
comparison to a high education level.28 
Risk factors 
It is hypothesized that the majority of women with GDM have beta cell dysfunction even 
before pregnancy, and have a form of chronic insulin resistance post-pregnancy when 
compared to non-GDM women post-pregnancy,29 although very little is known about the 
genetics in GDM women with chronic insulin resistance and its relation to T1DM.30 
However, studies have shown clustering of GDM instances in families, showing a 
familial tendency, and reoccurs in 30-91% women with a history of GDM depending on 
ethnicity and age.31 Other established risk factors for GDM include a past delivery of a 
macrosomic newborn (greater than 4000g birth weight), high parity, family history of 
diabetes mellitus and maternal birth weight.32,33 
Physical activity 
 In addition to ethnicity, genetic predisposition and maternal age, there are some 
modifiable risk factors for GDM. Physical activity appears to have a favorable effect in 
various insulin resistance syndromes. There is an acute improvement of insulin sensitivity 
even with mild physical activity and a long-term improvement with continued physical 
activity that results in reduction of adiposity and increase in lean muscle mass.34 A 2015 
meta-analysis described a 28% risk reduction of GDM in women who were placed in a 
physical activity regimen compared with those in control groups.35 Another meta-analysis 
from 2011 analyzed observational studies and found a significant protective effect 
(pooled OR 0.76 [0.70-0.83]) for exercise in early pregnancy.36 Knowler et al 37 reported 
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a decrease of insulin therapy for overweight women with GDM who participated in 
resistance exercise training during their pregnancy. Liu et al 38 showed that women who 
became physically active during early pregnancy had a lower rate of GDM than those 
who stayed inactive (1.6 vs 3.6%, p=0.004) and those who began physical activity and 
continued for 3 months had 59% lower unadjusted odds of GDM (OR 0.41, 95% CI 
[0.17-0.95]), even when adjusting for age, race/ethnicity, education, parity, pre-
pregnancy BMI and smoking. The same study demonstrated a lower GDM rate in women 
who reported brisk walking as their most common physical activity (1.6 vs 3.7% p= 
0.0167) compared to women who did not, and brisk walking was strongly associated with 
lower GDM risk when adjusting for the same co-variables mentioned earlier (OR 0.38, 
95% CI [0.16-0.89]).  
However, there have been some studies that have not been able to provide 
sufficient evidence to suggest that a regimen of physical activity benefits patients at risk 
for GDM compared to standard care, and that it is not cost-effective to perform weekly 
exercise for these patients.39 Dietary factors also play an important component in the 
development of GDM. There has been extensive studies of risk reduction and risk-
enhancing dietary components associations with T2DM, which suggest that total 
carbohydrate and fat intake are not necessarily risk-enhancing factors to T2DM, but 
specific kind of carbohydrates, such as whole grains40 41 42, may be protective while trans 
fatty acids and polyunsaturated fats may increase risk of T2DM43 44 in women and 
substitution of these fatty acids with nonhydrogenated polyunsaturated fatty acids will 
reduce T2DM risk.43  
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Diet 
A low glycemic index diet combined with a high fiber intake and lowest amount 
of processed refined grains reduces glycemic and insulin secretion responses therefore 
lowering the risk of T2DM.44 A 2004 prospective study demonstrated that higher intake 
of fat and minimized intake of carbohydrates (or substitution of carbohydrates with fat) 
may be associated with increased risk of GDM and impaired glucose tolerance (IGT).45 
However, GDM has not been studied extensively as IGT so the conclusion that dietary 
factors during pregnancy play a major role cannot be determined. Another large 
prospective study in 2006 by Zhang C. et al46, indicated pre-pregnancy diet is associated 
with the risk of glucose intolerance in pregnancy. The study compared two pre-gravid 
dietary patterns and their respective associations with GDM risk. One diet, comically 
named the Western diet, was composed of high intake of red meat, processed meat, 
refined grain products, sweets and large fatty carbohydrate loads. The other diet, termed 
prudent dietary pattern, consisted of fruits, green leafy vegetables, fish and poultry. GDM 
risk was significantly higher in pre-gravid women with high intake of red/processed 
meats (six servings per week, association may be attributed to increased iron intake)47, 
independently of BMI and adiposity percentage, compared to women who consumed two 
servings or less of red meat per week.  
Additionally, total fiber, cereal and fruit fiber consumption before pregnancy 
showed an inverse association with GDM risk.48 Total glycemic load was measured 
likewise, and calculated by multiplying the carbohydrate content of each food by the 
glycemic index value of the particular food type (number associated with the food's effect 
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on a person's blood level, a value of 100 represents the standard, an equivalent amount of 
pure glucose), then multiplied by its consumption frequency and finally all values were 
added to obtain a final total glycemic load. The prospective study validated that the 
combination of high glycemic load and low fiber was associated with a 2.15-fold 
increased risk of GDM compared with a glucose-fiber balanced diet.46 49  
Smoking 
Smoking has been associated with an increased risk in T2DM in women,50 but it 
has not been associated with increased maternal GDM. Nevertheless, there have been 
studies which have demonstrated a link between maternal smoking and gestational 
diabetes in the daughter,51,52 but more studies are needed to confirm a direct association. 
Maternal obesity has been linked to increased risk of GDM, with a positive correlation of 
increasing BMI, especially with increased visceral adiposity, as mentioned earlier. 53   
Alcohol consumption has been found to be associated with T2DM,54 and in another study 
seemed to contribute to increased GDM risk in low-educated populations.28 Male fetus 
has been associated with a worse beta-cell function, postprandial hyperglycemia and 
elevated risk of GDM in the mother.55 
Weight gain 
 In 2009, the Institute of Medicine (IOM) issued new guidelines for pregnancy 
weight gain.56 For singleton patients with a prepregnancy BMI of 25 to 29.9 kg/m2, it is 
recommended to add 15 to 25 lbs, while obese patients (BMI of 30 kg/m2 or more) 
should aim for 11 to 20 lbs. Women with a BMI greater than 25 kg/m2 or greater than 23 
kg/m2 in Asian Americans should be screened for Pre-gestational diabetes or early 
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GDM.57 In addition to being a risk factor for GDM, maternal obesity may cause cardio 
metabolic dysfunction and develop preeclampsia and obstructive sleep apnea.58  
 ACOG does not recommend to gain under the recommended value due to 
increased risk of neonates who are small for gestational age.58 Other studies have found 
that limiting gestational weight gain will not prevent development of GDM59, although 
the risk of undesirable outcomes does increase when gestational weight gain exceeds the 
range set by the IOM guidelines.60  
Complications and outcomes of GDM 
While GDM is described as a temporary condition that is resolved after delivery, it is 
associated with increased cardiovascular disease due to peripheral vascular dysfunction 
and metabolic abnormalities persisting after delivery. Peripheral vascular dysfunction 
may be caused by impaired endothelial function 61, rigidity of arterial walls (carotids and 
aorta) and impaired acetylcholine-induced vasodilation in extremities.62  
More immediate risks are related to delivery complications. The risk of preterm 
delivery is increased in women with GDM due to preeclampsia and hypertension 
disorders, which accounts for a little less of half of preterm deliveries.63 Preterm delivery 
is classified as a delivery, either induced or spontaneous, before 37 weeks of gestation.  
Even though a large case-control study in 1998 63 demonstrated no significant 
relationship between GDM and preeclampsia (OR 1.27, 95% CI 0.52-3.15), the HAPO 
observational study (Hyperglycemia and Adverse Pregnancy Outcomes), published by 
the New England Journal of Medicine in 2008,64 found a significant association between 
hyperglycemia and preeclampsia. There was a small significant positive relationship 
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between elevated 1 hour and 2 hour OGTT levels and preterm delivery, although there 
was no differentiation between induced and spontaneous deliveries in this study. In fact, a 
retrospective study by Yogev et al. with 1,526 patients diagnosed with GDM showed that 
the rate of spontaneous preterm deliveries among GDM mothers (10.7%) was almost 
equivalent to the rate of spontaneous preterm deliveries among non-GDM mothers 
(11.3%), 65 while a cohort study of 46,230 pregnancies showed a significant higher risk 
of spontaneous preterm deliveries in patients with GDM vs patients with normal 
screening (6.7% vs 4%).66  
However, GDM patients with spontaneous preterm deliveries in Yogev et al. were 
categorized by higher OGTT glucose values and higher mean blood glucose than patients 
with GDM with non-spontaneous preterm deliveries and well controlled glycemic levels. 
Spontaneous preterm delivery was more frequent in patients with poorly controlled 
GDM. Consequently, monitoring and controlling blood glucose levels will most likely 
decrease the risk of a spontaneous preterm delivery.65 Of note, the same large case-
control study in 1998 showed strong association with pregnancy-induced hypertension 
among women who received less prenatal care and African American women.67  
In patients with pre-gestational diabetes, there is a risk of stillbirth if the fetus is 
delivered past term. Therefore, these patients are induced to prevent intrauterine fetal 
demise (IUFD). Patients with T1DM or T2DM were unlikely to have a successful 
pregnancy before the discovery of insulin, and perinatal mortality rate was close to 65% 
and maternal mortality approximately 30%.68 After the discovery of insulin and the 
understanding of diabetes mellitus, perinatal mortality rate dropped dramatically, even 
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though the risk of fetal death was and is still dependent on race (primarily non-Hispanic 
black women), young maternal age under 19, old maternal age and multiple gestations.69 
A study published in 200070 reported the risk of IUFD was greater in T2DM than T1DM, 
due to less stringent glucose control in T2DM patients (34/1000 stillbirths in T2DM vs 
12/1000 stillbirths in T1DM). The prognosis was worse if the patient had been newly 
diagnosed with T2DM. O’Sullivan et al71 found a perinatal mortality rate of 64 births per 
1000 in patients with GDM in the 1970s.  
Beischer et al72 found that screening routinely for GDM improved significantly 
the perinatal outcome, and that similar to diabetes mellitus in the total population, the 
prevalence of GDM had increased over time. Several studies have shown that women 
diagnosed with GDM had a higher incidence of stillbirth in prior pregnancies73 and that 
women with metabolic syndrome (aka pre-diabetes) had a higher risk of stillbirth 
compared to nondiabetic women (rate of 19.7 intrauterine fetal demise (IUFD) vs 5.5 per 
1000).74 Still other studies have argued that there is no association between GDM and 
fetal death,75 especially in populations where fetal death is common like Mozambique. 
This is important to consider, since there are multiple causes of stillbirth as mentioned 
above, that are not complicated by hyperglycemia alone, and women with GDM tend to 
have other cofactors that promote risks of stillbirth, like advanced maternal age and 
Hispanic ethnicity.76  
The American Diabetes Association recommends inducing delivery at 38 weeks 
of gestation while ACOG opposes delivery before 39 weeks unless patient has failed in-
hospital attempts of glycemic control and this surpasses risks to neonate.57 Less fetal 
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macrosomia births and shoulder dystocia events have been observed in deliveries at 38 
weeks,77 but the outcomes of delivering before 39 weeks GA have been associated with 
NICU admissions78 and excess morbidities seen in neonates.79 The risk of expectant 
management carries a higher risk (but in itself is low) of stillbirth than the risk of 
delivering between 39 weeks to 40 weeks of gestation in women with GDM, although 
caution should be taken when making clinical recommendations if gestational age is not 
accurate or reliable. 76  
Delivering a fetus electively in the early term period given the elevated risk of 
IUFD has critical complications including respiratory distress syndrome (RDS) and 
transient tachypnea of the newborn (TTN).  Lung maturation in fetuses of diabetic 
mothers is often delayed and has been linked to hyperinsulinemia and hyperglycemia.80 81 
After 38 weeks’ gestation, The Fifth International Workshop Conference on GDM does 
not recommend testing lung maturity if delivery is indicated.82 Evidence has shown that 
elective induction or cesarean section if attempted before 38 weeks of gestation can 
increase the risk of requiring supplemental oxygen or needing ventilator assistance.80 81 
Infants born at 37 weeks were twice as likely to need ventilator assistance compared to 
babies with GA of 38 to 40 weeks, while infants born at 36 weeks were five times as 
likely, and 35 week gestation births were nine times as likely.83 Approximately 8% of 
newborns born (in the United States) between 35 and 36 weeks require supplemental 
oxygenation, and are more likely to be re-hospitalized within 182 days after discharge.83 
Administration of corticosteroids for enhancement of fetal lung maturity is not 
 16 
contraindicated with a diagnosis of GDM, however a more strict maternal glucose 
monitoring and additional insulin doses may be necessary.82 
The risk of shoulder dystocia and birth trauma increases with increased birth 
weight, and the rate of shoulder dystocia is higher in diabetic women vs nondiabetic 
women for each 0.25 kg increase in fetal weight. Shoulder dystocia, when the anterior 
shoulder of the newborn is wedged under the maternal pubic symphysis during pushing,  
complicates 35% to 45% of assisted deliveries of nondiabetic mothers.84 This difference 
in risk of shoulder dystocia in newborns has been attributed to truncal obesity, wide 
shoulder diameter,85 and the maternal obesity. Birth trauma includes fracture of the 
humerus and/or clavicle, injury to the brachial plexus, and facial palsy. Birth trauma 
results from shoulder dystocia complications, with brachial plexus being the most 
critical.84 In 1993, Combs et al86 stated elective induction of labor (IOL) increased the 
cesarean rate compared to spontaneous labor (57% vs 31% rate, p<0.01). 
Notwithstanding, a recent study showed that induction of labor at 38 weeks reduced the 
risk of shoulder dystocia (8/407; 2 % compared with expectant management 25/411; 6 %) 
when fetal macrosomia was suspected, and did not affect the risk of a cesarean section.87 
The American Journal of Obstetrics and Gynecology (AJOG) published a 2016 study that 
found a decreased risk of cesarean delivery in patients with GDM who had undergone 
IOL at 38 or 39 weeks of gestation compared to expectant management. However, the 
study also found an association of induction at 38 weeks with an increased risk of 
neonatal intensive care admission.88   ACOG57 endorses expectant management in 
women with A1GDM up to 40 +6 weeks of gestation if antepartum testing is suitable. 
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For women with well controlled Type 2 GDM (A2GDM), time of delivery should be 
from 39 weeks to 39+6 weeks of gestation, and if GDM is poorly controlled, risks of 
prematurity and stillbirth should be taken into consideration. ACOG also recommends 
cesarean section if the estimated fetal weight (EFW) is greater than 5000g in women 
without diabetes and greater than 4500g in women with GDM, or preGDM. However, 
sensitivity when screening for macrosomia is low, indicating inaccuracy therefore it 
cannot be diagnosed or predicted,89 despite new sonographic methods to estimate 
birthweight or fetal hemodynamic indices.86 87 
Existing research on GDM delivery outcomes 
The HAPO64 study in 2008 which reviewed adverse pregnancy outcomes of 
hyperglycemia, found that neonates born to hyperglycemic women were large for 
gestational age (LGA) above the 90th percentile, had greater frequency of cesarean 
section, most likely to be hypoglycemic, and greater than the 90th percentile of cord-
blood serum C peptide (meaning insulin secretion was elevated). The frequency of these 
events had a positive correlation with the glucose category which were characterized by 
the measure of fasting plasma glucose, 1 and 2-hour plasma measure of hyperglycemia. 
The higher the category, the higher the maternal glucose levels were. Clinical neonatal 
hypoglycemia had a less apparent correlation with maternal hyperglycemia compared to 
other outcomes, in which 2.1% neonates born to the lowest maternal glucose category 
had clinical hypoglycemia, while the frequency of neonatal hypoglycemia for neonates 
born to the mothers with the most elevated hyperglycemia was 4.6%. Compared to the 
more substantial differences that were seen in the other outcomes, (for example the 
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frequency difference between the lowest and highest categories; were 5.3% vs 26.3% for 
birth weight above the 90th percentile, 13.3% vs 27.9% for primary cesarean section, and 
3.7% vs 32.4% for hyperinsulinemia above the 90th percentile) the clinical neonatal 
hypoglycemia had the smallest difference when accounting maternal glucose levels. 
When confounding for other factors, the secondary outcomes revealed positive strong 
associations between preeclampsia, shoulder dystocia and/or birth injury. Intensive 
neonatal care and hyperbilirubinemia were associated with the 1-hour and 2-hour plasma 
glucose levels, but fasting glucose levels were not accurate predictors. There was no 
association seen between LGA or birth weight below the 10th percentile and maternal 
hyperglycemia. It is important to state that the women in this study did not have GDM or 
pre-GDM. However, two primary outcomes that are known to complicate pregnancies in 
mothers with GDM/pre-GDM were also seen in non-GDM patients with hyperglycemia. 
The study further supports that maternal hyperglycemia, even less severe than what is 
observed in diabetes mellitus, is associated with similar clinical prenatal conditions as 
GDM, therefore treating hyperglycemia without the diagnosis of GDM based on previous 
criteria, may reduce these effects.  
The 2005 Australian Carbohydrate Intolerance Study in Pregnant Women trial78, 
assessed if the treatment of gestational diabetes would reduce perinatal complications and 
analyzed the effects of treatment on maternal outcome, mood, and quality of life. 
Through randomization, patients in the intervention group received a diagnosis of glucose 
intolerance and were assigned the plan for intervention. Patients randomized in the 
routine-care group were informed they did not have GDM (after agreeing to participate in 
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the study). The treatment for the intervention group consisted of ongoing care by the 
obstetrical team including individualized dietary advice from a certified dietician taking 
into account the patients pre-gravid weight, diet, lifestyle and pregnancy weight gain. The 
patients were instructed to self-monitor their glucose levels four times a day, insulin 
therapy adjusted on basis of glucose levels. The study found the rate of fetal death, 
shoulder dystocia, clavicular fracture and nerve palsy were significantly lower in the 
intervention group compared to the routine-care group; 1% vs 4%, p=0.01, with 
adjustments of maternal age and race/ethnicity. Interestingly, the percentage of infants 
requiring admission to the neonatal nursery was higher in the intervention group (71%) 
compared to the routine-care group (61%), although there were no differences of fetal 
hypoglycemia and length of admission between these groups. The study attributed the 
increase of NICU admission to the knowledge of the diagnosis by the physicians. 
Treatment reduced the percentage of LGA from 22% to 13%, macrosomia from 21% to 
10%, however other findings (SGA, 5-min Apgar score, IV therapy for hypoglycemia, 
neonatal convulsions and respiratory distress syndrome) remained similar despite 
treatment. There was no difference between the rates of cesarean delivery, however, the 
frequency of induction was higher in the intervention group (39% vs 29%) due to the 
knowledge of diagnosis.  
In 200992 randomized controlled trial evaluated whether treatment of women with 
mild GDM reduces obstetrical complications and perinatal morbidities. They found 
comparable results to the 2005 Australian Carbohydrate Intolerance Study in Pregnant 
Women trial. In both of the studies, the rates of hypoglycemia and hyperbilirubinemia did 
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not differ between the groups, and antenatal preeclampsia, shoulder dystocia, LGA and 
fetal macrosomia were reduced in the treatment group. However, the treatment group in 
this study had a lower rate of cesarean sections (26.9% vs 33.8%, p=0.02) when adjusting 
for abnormal presentations and other obstetrical complications unrelated to GDM. 
Induction of labor remained the same in both groups. One limitation of the study was 
inability to monitor glucose levels in the control group, therefore it was not known if 
rigorous treatment of GDM reduced glycemic levels relative to regular obstetrical care.  
Recommendations based on research 
The American Diabetes Association recommends screening for GDM at 24-28 weeks of 
gestation. Women with T1DM or T2DM should be counseled about preconception, and 
about the risk of development of diabetic retinopathy during pregnancy, and advised to 
maintain glycemic levels in reference range (HA1c < 6.5%) to minimize the possibility of 
fetal congenital anomalies. Due to risk of retinopathy, trimestral eye examination is 
recommended if initial eye exam was abnormal.93 
The International Association of Diabetes and Pregnancy Study Groups 
(IADPSG) states that women who are high risk and are found to have diabetes in their 
initial prenatal visit receive a diagnosis of diabetes mellitus, not GDM. This was done 
after consideration from the American Diabetes Association and multiple obstetrical 
organizations of the increased incidence of type 2 diabetes in women of childbearing age, 
which ended in pregnant women with undiagnosed type 2 diabetes.1 A study of 4507 
women showed that for the 302 compliant patients who were diagnosed with GDM by 
the end of the study (using OGTT) , only 4% were identified at their first prenatal visit –
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before 24 weeks- using fasting plasma glucose. Therefore, fasting plasma glucose 
screening test at the first prenatal appointment has poor specificity which makes it 
inefficient screening for GDM.94  
Initially, GDM diagnosis criteria was established by O’Sullivan in 1964, but the 
criteria was changed by the National Diabetes Data Group (NDDG) in 1979. In 1982, 
Carpenter and Coustan (C&C) proposed to modify the plasma glucose parameters, which 
was adopted shortly by the ADA and ACOG.94 The C&C criteria follows a two-step 
process and is the approach most commonly and currently used in the United States. 95 
The initial screening test is composed of a 50g oral glucose solution ingestion followed 
by a 1 hour venous glucose measurement. The patient does not need to fast for this part of 
the test. If the value is elevated (greater than 130-140 mg/dL, depending on the provider’s 
preferences), the patient screened positive therefore a 100 g OGTT is performed.96 
In the HAPO study, diagnostic parameters for GDM were a fasting plasma glucose 
less than 105 mg/dL and a 2-hour plasma glucose level less than 200 mg/dL after a 75 
gram OGTT between 28 weeks to 32 weeks of gestation.64 Due to the outcomes found in 
the HAPO study, the IADPSG and ADA1 now recommend the guidelines shown on 
Table 1 for the diagnosis of GDM. A single elevated value on any of the categories of 
plasma glucose would be diagnostic of GDM after a 75 gram glucose load. 93  
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Table 1. Diagnostic Criteria for GDM 
 NDDG (in 
mg/dL) 
C&C (50g 
followed by 100g 
OGTT) 
IADPSG based on 
HAPO study (75g 
OGTT) 
Fasting plasma 
glucose 
≥105 ≥95 ≥ 92 
1-hour  ≥190 ≥180 ≥180 
2-hour  ≥165 ≥154 ≥153 
3-hour  ≥145 ≥140 ≥140 
 
The IADPSG also recommends that women with a fasting plasma glucose in the 
range of 92 mg/dL and 126 mg/dL during the first trimester be diagnosed with GDM. A 
fasting glucose value greater than 126 mg/dL might be indicative of overt T2DM, if not 
assessed in the initial prenatal visit.93  
The National Institute of Health (NIH) recommended continuation of the two-step 
approach of GDM screening after much deliberation. NIH concluded that the adoption of 
the one-step process would increase the prevalence of GDM from 5-9% to 15-20%, 
therefore increasing direct and indirect health cost with insufficient evidence of improved 
health outcomes.1 NIH also stated concern that the new diagnosis of GDM in women 
with low range hyperglycemia may have unintentional consequences, such as increase in 
cesarean deliveries78, life disruptions and psychosocial burdens.97 Potential benefits in 
adopting the two-step process include an international diagnostic standard that would 
allow better standardization of best patient care practices and unification of research 
outcomes.98 The concerns for negative implications of the increased rate of diagnosis 
were tested in a retrospective cohort study comparing different parameters for two step 
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testing.94 The 2016 study compared outcomes of 952 women screened using the IADPSG 
criteria, and 888 women by C&C criteria. The results showed that the prevalence of 
GDM was substantially higher in the IADPSG group (13.44% vs 2.59%), the risk of 
primary cesarean section was reduced in the IADPSG group (21.7% vs 24.7%). The 
IADPSH group also had reduced fetal outcomes for birthweight under 90th percentile, 
jaundice, admission to NICU, birth trauma and neonatal hypoglycemia. When 
individually analyzed, the fetal outcomes were not significantly different in both 
groups.94 Other studies have shown a reduction in risk of gestational hypertension, 
prematurity, cesarean section, LGA, low 1-minute Apgar score, NICU admissions,99 
polyhydramnios and pre-eclampsia using IADPSG criteria compared to Carpenter and 
Coustan criteria.100 Another study in 2014 comparing the 1-step approach vs the 2-step 
approach in high risk pregnancies found there were no disparities between the groups for 
the mode of delivery, birth weight or Apgar score. However, they found significant 
differences in the compliance of screening, and attributed it to the longer interval it takes 
to complete the 2-step approach.101 Further research needs to be done in order to resolve 
the uncertainty of which approach would be the best to implement in the fullness of time. 
Also, it is important to consider the population’s ethnicity since it may be reasonable to 
vary the screening threshold to equilibrate sensitivities and specificities among different 
ethnic groups and reduce false positive results, but more research needs to be completed 
in order to determine the ideal thresholds. 102 
Glycemic levels in non-obese, non-diabetic without evidence of congenital 
malformations related to hyperglycemia were reviewed in two studies. Parretti et al 103 
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selected 51 from 66 Caucasian pregnant women with a normal 1-hour GTT (mean 115.8 
mg/dL) who delivered to term without congenital malformation. Subjects were taught to 
monitor their blood glucose from 28-38 weeks without lifestyle modifications or dietary 
restrictions. The results showed a daily mean glucose reading of 71.9 mg/dL (SD 5.7 
mg/dL) at the beginning of 28 weeks and a daily mean glucose reading of 78.3 mg/dL 
(SD 5.4 mg/dL) reaching 38 weeks of gestation. The increase of glucose levels from 28 
weeks to 38 weeks is explained by the decrease in insulin sensitivity as pregnancy 
advances. 3 4 The study found that the 1-hour postprandial glucose values positively 
correlated with fetal abdominal growth as early as 28 weeks, and was preserved 
throughout the third trimester, which indicates that 1-hour postprandial glucose readings 
are good predictors of infant birth weight and supports The National Institute of Child 
Health and Human Development—Diabetes in Early Pregnancy Study.104  However, the 
study is limited by lack of generalizability due to its non-diverse subject population. In 
Yogev et al’s study 105, obese and non-obese women without a diagnosis of diabetes 
mellitus were evaluated for 72 consecutive hours. The mean fasting blood glucose level 
for the study group was 75 mg/dL (SD 12 mg/dL), and mean blood glucose level was 
83.7 mg/dL (SD 18 mg/dL). The average time needed to reach a postprandial peak 
glucose value of 110 mg/dL (SD 16 mg/dL), which was the mean postprandial peak 
glucose reading, was 70 minutes (SD 13 minutes). Obese women were characterized by 
elevated postprandial glucose values—for 1, 2 hour postprandial and postprandial peak 
values—and had a significantly lower mean blood glucose value at night. Interestingly, 
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there was no difference between obese and non-obese patients in fasting and mean blood 
glucose values.  
The Fifth International Workshop Conference82 and ADA93 recommend the following 
values as targets for maternal capillary glucose concentrations: 
• Pre-prandial glucose value less than or equal to 95 mg/dL 
• One-hour post-prandial glucose value less than or equal to 140 mg/dL 
• Two-hour post-prandial glucose value less than or equal to 120 mg/dL 
These values are for newly diagnosed diabetes in pregnancy. For pregnant women with 
overt T1DM or T2DM, the glycemic goals for fasting, pre-prandial and overnight glucose 
are between 60-99 mg/dL. Peak post-prandial glucose levels should remain between 100-
129 mg/dL and HbgA1c under 6.0%. 106 
Nonpharmacological treatments 
Lifestyle interventions should be the primary therapeutic strategy for patients with GDM. 
A 2017 meta-analysis that evaluated the effects of lifestyle interventions with and without 
pharmacotherapy in the treatment of GDM reviewed 15 trials (total of 4501 women) and 
found that more women in the intervention group had met their desired postpartum 
weight within one year versus the control group.107 108 Postpartum depression was also 
decreased compared to the control group.78 108 Fetal adverse outcomes were also 
decreased in the experimental group; LGA risk was reduced as well as birthweight, 
macrosomia, and neonatal fat mass. 78 108 109 Lifestyle interventions should include diet, 
physical activity, education about GDM, education about self-monitoring and other types 
of interventions the provider believes is appropriate for an individual patient.  
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Cost of GDM 
The cost of gestational diabetes imposes a significant financial burden. Few studies have 
analyzed the cost implication GDM can contribute to health care costs. In 2007, there 
were approximately 180,000 cases of GDM in the United States. GDM is associated with 
a significant increase in ambulatory visits due to pregnancy complications, both maternal 
and fetal. The total national cost attributable to GDM in that year was $596 million 
increase for maternal care, roughly $3,305 per mother diagnosed with GDM. Ambulatory 
visits due to complications caused by GDM amounted to $130 million, while total 
ambulatory visits by mothers with GDM incurred $418 million.110 111 Eight percent, ($51 
million) of the costs attributed to GDM are paid by the patient.110 In 2012, the cost of an 
uncomplicated vaginal delivery was $9,775, compared to $15,041 for an uncomplicated 
cesarean delivery.112 In a pre-term delivery, cost of delivery increases dramatically to 
$45,000 per delivery, costing $26.2 billion nationwide.113 
 In the past 3 decades, 84% of pregnant patients between the ages of 25 and 34 
received care in the first trimester, compared to patients under 20 years of age (34%).114 
A 1997 study evaluated the effectiveness of encouragements for improving compliance 
with the first prenatal visit. The study found that women receiving a transportation 
voucher had a compliance rate of 82% vs 60% of the control group.115 
Telemedicine 
Telemedicine incorporates the diagnosis and treatment of patients with 
telecommunications technology. Telemedicine systems have been used in diabetes care, 
and have been shown to have potential benefits by improving communication between 
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patient and provider, allowing providers to assess the condition of the patient weekly, 
helping to manage diabetes and by educating the patient in making the right decisions in 
regard to their condition.116 When telemedicine has been integrated into the treatment of 
women with gestational diabetes, studies have shown that the number of check-ups or 
outpatient clinic visits are reduced in interventional groups compared to control groups. 
One study showed improvement in 3rd trimester metabolic control and a reduction in 
cesarean sections and macrosomia rates,117 while another study showed no significant 
differences regarding metabolic control and birth complications but supported the 
decreased need of outpatient clinic visits.118 It is important, however, to educate the 
patient on the frequent use of telemedicine system to appreciate a potential benefit in 
metabolic control, which can be a possibility when treating GDM in underserved 
women.119   
Telemedicine and Preexisting DM 
An application called Few Touch was developed for people with T2DM aged 44-
70. To determine if such tools could support lifestyle changes in patients with T2DM, 
user feedback for a 6-month intervention was analyzed and was found to support good 
usability of the system. The design of the Few Touch Application included three 
functionalities for the study: blood-glucose sensor system (connected via Bluetooth), a 
nutrition habit registration system (manual input choosing food type) and physical 
activity sensor system (step counter). Diet recording required manual input, which some 
users found laborious, however, there was an improvement in the increase of fruit and 
vegetable daily intake. The physical activity sensor included a pedometer connected via 
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Bluetooth to the mobile device. Users transferred data by tapping on a button of the app 
an average of 0.9 times a day. On average, users checked their physical activity graph 
once per day. While this system sounds promising, there was some difficulty 
implementing this system due to battery life of pedometer, troubleshooting and 
transferring of information or other problems concerning the lack of versatility when 
wearing the pedometer, as it was required to use a belt in order to carry the pedometer 
correctly. However, 8 out of 12 users were satisfied, and increased their physical activity 
(20% increase in the number of steps) The users received automatic feedback from the 
application, depending on their status of their goals in regards to diet and physical 
activity, which they seemed to appreciate, especially the food-related texts.120 The 
limitation of this study were the small sample of patients who tested the Few Touch 
application, and involvement of the users in the design of the application, therefore the 
feedback might have been not as positive with an unbiased cohort. 
Other functionalities, such as health care professional control in the therapy and 
real-time communication would allow distant interaction with the patient’s insulin pump 
(if needed), glucometer or continuous glucose monitor through a secure network. This 
secure network can be achieved by establishing a connection between the medical 
devices and a mobile device (Bluetooth or wireless internet), and then using the patients 
personal network for data transferring.121 
A recent article released in 2014 described the process on clinical practice 
guidelines using a telemedicine system called MobiGuide for patient guidance. They 
provided a methodology that encompassed the components of a smartphone application, 
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the formalization of the guideline into workflows and patient-friendly advice to be 
created in MobiGuide.  The main elements of the Mobiguide system included a decision 
support system, meant for the representation computer-interpretable guidelines, a body 
area network that provides instant monitoring of signals supported by a mobile 
application that connects with the back-end server and operates communications between 
different sections of the mobile application, a secured personal health record that is 
accessible and merges user’s information from the body area network to the user’s data in 
the hospital EMR. Finally, a knowledge base containing computer-interpretable 
guidelines. The internal structure of the smartphone user interface is composed of various 
components (data controller, secure storage controller, messaging, etc.) which facilitate 
the efficiency and ease of use for the patient. 122 
iGlucose system by Smart Meter provides another way of conveying blood 
glucose information to the healthcare team. It uses cell-technology to transmit blood 
glucose results, information is available to the patient through a personal web portal in 
which the patient can log in to access information and modify settings. The patient’s data 
is uploaded with an assigned unidentifiable number corresponding for the respective 
patient, and then downloaded to a portal for the healthcare team to see immediately. The 
system also counts with virtual care coaching, enabling text communication between 
patient and provider, test reminders, notifications and alerts (for hypoglycemia or 
hyperglycemia). This system can actually provide an efficient and effortless way to 
deliver information without the need of recording it the traditional way or verifying that 
the wireless Bluetooth glucose meter is connected to a smartphone.123 
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Existing Research on GDM using Telemedicine 
Given et al. 124 conducted a feasibility study for a randomized controlled trial that 
explored the potential for telemedicine in the treatment of GDM. The control group was 
given usual care (blood glucose monitoring and attend a specialist diabetes clinic at least 
every 2 weeks) while the intervention group was given the usual care plus the use of a 
device that allowed weekly transmission of data to the medical team. In addition to a 
glucose meter, patients in the intervention group also received a set of scales, blood 
pressure monitor, and a telemedicine hub installed in the patient’s home. The 
telemedicine hub asked for compliance of insulin, hypoglycemic events and recent 
illnesses. Information was reviewed a day or two after it was finalized. IF there were any 
problems derived by the telemedicine data, health care providers contacted the patient to 
discuss readjustment of treatment or to arrange an appointment to reassess in person. 
Patient satisfaction was measured by completing a questionnaire at 36-38 weeks of 
gestation. Participants from both groups were satisfied, but participants in the 
intervention group identified several potential benefits including convenience of skipping 
appointments, reassurance, and avoiding travel time. 89.4% of the participants in the 
intervention group strongly agreed that they were satisfied with the system and would use 
it again. However, while participants found the telemedicine equipment straightforward, 
many found that the transmission of data was delayed (more than 20 minutes) and that 
caused inconvenience for one of the participants. Limitations in this study included 
restriction to access of patient data, as the data was presented in a long list that was 
difficult to interpret. Participants also felt that the opportunity to ask questions was lost in 
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the intervention group, given that they felt more comfortable discussing small topics in a 
private office setting versus a phone call. Another limitation was that this sample was a 
self-selected group, and any patients with aversion towards technology would have 
declined to be part of the study.  
  In a Spanish study, a web-based telemedicine platform was designed to evaluate 
patients remotely by viewing their input data transmitted from their glucose meter 
directly to the cloud and presented in an electronic logbook for the physician. The system 
prioritized the physician’s view according to patient’s metabolic condition. Using 
decision support tools, the platform made diet recommendations automatically, while 
insulin recommendations were notified to the physician to approve. The goal of the study 
was to evaluate effectives of the system and observe the impact in the time required to 
assess or see a patient, frequency of face-to-face visits, patients’ compliance to self-
monitoring and patients’ satisfaction. The study revealed that the time devoted by 
physicians for patients’ evaluation was reduced by 27% and ambulatory visits were 
reduced by 89%. Monitoring frequency was not decreased, as patients’ average number 
of blood glucose measurements averaged 3.89 times a day and sent data every 3.477 
days. There were some discordances between the medical team and the system’s 
recommendations (20 out of 75 therapy adjustments made by clinicians), nutritionists 
accepted 27 out of the 60 initial diet therapies proposed by the system, but rectified only 
3 out of the 29 diet adjustments that were suggested by the system. However, the number 
of visits in the intervention group was less (0.367 ± 0.901 visits) compared to the control 
group (3.207 ± 2.846 visits), which the majority of the physicians found favorable.125 
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 A proposed trial was published in 2016 to compare the efficacy of a smartphone-
based blood glucose management system with standard clinic care in GDM. The primary 
outcome is mean BG with corrections for number of measurements, percentage of pre-
prandial and postprandial reading and length of care. The secondary objective of the 
proposed study is to compare the control and intervention group for compliance to the 
allocated blood glucose regime, maternal and neonatal outcomes, glycemic control (using 
HbA1c) and patient attitudes. The strength of this study is that the study will take place 
within the maternity diabetes service of a National Health Service hospital in London, 
thus obtaining data in real-life scenario. Limitations include population sample that is 
uniform and similar, where the study will be conducted in a single tertiary center where 
women have low levels of social deprivation and high rates of literacy. Another limitation 
is that outcomes related to GDM, such as shoulder dystocia, birth trauma or stillbirth, will 
not be measured, which are risks highly associated with GDM. 126 
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METHODS 
Study design 
The prospective study will be a multicenter, open cohort randomized clinical trial of 
wireless glucometer with smartphone device vs. traditional glucose monitoring in patients 
with gestational diabetes mellitus.  
Study population and sampling 
The patients will be recruited over a period of 24 months from outpatient antenatal clinics 
at 5 major academic institutions in Boston, including Boston Medical Center, Brigham 
and Women’s Hospital, St. Elizabeth’s Medical Center, Beth Israel Deaconess Medical 
Center and Massachusetts General Hospital.  
Expected estimated sample size is 400 patients currently pregnant and with a new 
diagnosis of GDM. Estimation of sample size is based on 5% margin of error for a 
population size of approximately half a million patients (women diagnosed with GDM in 
the United States at a given year)127 and a 95% confidence interval. Eligible participants 
in the study include patients over the age of 18 who are diagnosed with GDM at the 
standard screening of GDM, between the gestational age of 24 weeks to 28 weeks. The 
diagnostic criteria will be based on the ACOG guidelines using the two-step process.96 If 
non-fasting, initial oral glucose challenge test consists of consuming a 50mg oral glucose 
solution, and blood glucose levels will be checked 1 hour after. If the value falls above 
135 mg/dL, the patient screened positive. If the value is greater than 180 mg/dL, the 
patient is diagnosed with GDM and does not need to transition to the second step. For 
values between 135 and 180 mg/dL, the patient will transition to the oral glucose 
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tolerance test, in which the patient will be asked to fast before coming into the next 
appointment. Fasting blood glucose values should fall under 95 mg/dL to be considered 
normal. The patient then will be given a 100g oral glucose solution as the tolerance test. 
Venous blood glucose measurement will be checked 1hr, 2hrs and 3 hours after ingestion. 
Any value above thresholds will confirm the diagnosis of GDM. Threshold values and 
inclusion criteria were resumed on Table 2. 
Table 2. Inclusion and Exclusion Criteria for Patients 
Inclusion Exclusion 
1. Patients over the age of 18. 
2. Patients will have a diagnosis of 
Gestational diabetes at 24 weeks to 
30 weeks of gestation. 
3. Required thresholds for GDM 
diagnosis following ACOG, after a 
positive oral glucose challenge 
test: 
• Fasting glucose greater or 
equal to 95 mg/dL 
• 1 hr 100g OGCT greater or 
equal to 180 mg/dL 
• 2 hr 100g OGCT greater or 
equal to 154 mg/dL 
1. Patients with diagnosis of 
gestational diabetes prior to 24 
weeks of gestation. 
2. Patients with obstetric history of 
preterm delivery, macrosomia, 
respiratory distress syndrome or 
congenital defects.  
3. Patients with Type 2 or Type 1 
diabetes mellitus.  
4. Patients who smoke tobacco, 
cannabis, drug users, or uses 
alcohol during pregnancy.  
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• 3 hr 100g OGTT greater or 
equal to 140 mg/dL 
• If patient’s initial OGCT 
was greater than 180 
mg/dL, confirmation of 
GDM diagnosis does not 
need OGTT. 
4. Patients should have access to a 
mobile device to receive 
notifications. 
5. Patients should have reliable 
access to transportation for 
prenatal visits. 
5. Patients who have been recently 
treated with systemic 
corticosteroids or will be treated.  
6. Patients who speak a language that 
is not available on iGlucose 
system. 
 
Intervention 
The eligible study population will be randomized into two groups based on a complete 
list of patients from the selected medical centers. The subject will be randomized after 
initial prescription of insulin, metformin or non-pharmacological treatment based on 
patient’s needs and risk factors. The control group will receive traditional treatment for 
gestational diabetes. Patients will be asked to check their blood glucose levels (finger 
stick) four times a day: first when waking up before eating breakfast, second before 
lunch, third before dinner and lastly before going to bed. They will be taught how to 
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adjust their insulin (if taking it) depending on the BG measurement. The BG values will 
be recorded on a small, portable booklet. At each prenatal visit, the BG values will be 
evaluated and the patient assessed for continuation or adjustment of treatment. Prenatal 
visits will be scheduled once a week.  
 The intervention group will follow similar recommendations as the control group, 
however, they will not annotate their BG readings in the booklet. Patients in this group 
will receive an iGlucose glucometer. This glucometer will be ready to use when given to 
the patient, and will contain patient’s information and decode it when sending 
information to the cloud. In addition, the patient will be taught to use the Personal Web 
Portal to access her information and be able to contact an obstetrics nurse if needed. The 
patient will also have her mobile device linked to the device, and receive virtual message 
coaching in regards to her care. Patients in this group will be assessed real time and if 
adjustments need to be done to her medication, a nurse will contact the patient to inform 
her of the change in dosage or medication. If the patient feels the medication is working, 
without side effects or any concerning symptoms, she may opt out of her next scheduled 
appointment. If the medication is not working, or the patient is complaining of 
concerning symptoms, she will have the option to schedule an appointment within less 
than a week. 
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Image 1. iGlucose system layout123 
 
Study variables and measures 
The primary outcome will be postprandial capillary glucose readings within the 
controlled range in the intervention group. Glucose targets have been established by 
ADA and ACOG as a fasting glucose of less than 95 mg/dL, one-hour postprandial blood 
glucose concentration less than 140 mg/dL or a two-hour postprandial glucose 
concentration less than 120 mg/dL. Another primary outcome that will be observed is 
decreased frequency of scheduled prenatal visits in the intervention group compared with 
the control group. Number of missed appointments in both groups will count as prenatal 
visits, but will be compared as a secondary outcome, where the intervention group will 
have less missed appointments.  
Additional secondary variables to be collected include type of treatment (non-
pharmacological, insulin or oral medication (glyburide, metformin), race, age, parity, 
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BMI, primary language, education level, maternal obstetric complications (pre-eclampsia, 
hypertension) and location of obstetrics care. 
Recruitment 
Subjects will be referred to the study from 5 antenatal clinics from medical centers in 
Boston. These are Boston Medical Center, Brigham and Women’s Hospital, St. 
Elizabeth’s Medical Center, Beth Israel Deaconess Medical Center and Massachusetts 
General Hospital. Participants will be recruited by obstetric nurses and specialists. 
Obstetric nurses and providers will review the patient’s obstetric history with them to 
determine eligibility and ask if the patient will be willing to participate in a study to 
obtain informed consent after the diagnosis of GDM is confirmed.  
Data collection 
Participants who agree to take part in the study will have undergone a complete medical 
and obstetrics history. For the intervention group, blood glucose data will be obtained 
from the iGlucose system. Information will travel from the wireless device to the cloud. 
Patient information is uploaded to the cloud encrypted, then decoded when downloaded 
to the Population Management Portable that can be viewed by the provider. Frequency of 
scheduled visits will be noted by the obstetrics team.  
For the control group, weekly blood glucose data will be collected at every follow 
up visit. If more than 90% of FS readings are within range, patient may return in two 
weeks instead of one. Number of scheduled visits and appearances will be quantified.  
Information will be de-identified in both groups and later analyzed.  
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Data analysis 
We will be fitting two regression models, one for each outcome of interest. We expect 
that the first primary outcome, pre-prandial capillary glucose, follows a normal 
distribution. Thus, we will use a linear regression to predict the mean capillary glucose 
with the following covariates: group assignment (control or intervention), type of 
treatment (non-pharmacological, insulin or metformin), race, age, parity, BMI, 
hypertension, and location of obstetrics care. After fitting model, a 2-sided t-test will be 
performed on the coefficient belonging to group assignment with the null hypothesis that 
the coefficient is equal to zero. 
Next, the second primary outcome, number of prenatal visits, is continuous data; 
therefore, we will use a Poisson regression with the same covariates listed above. 
Afterwards, we perform a one-sided t-test on the coefficient belonging to group 
assignments with the null hypothesis that the coefficient is equal or greater than zero, 
since we are interested in observing a significantly lower frequency of visits in the 
intervention group. If over-dispersion (data displays larger variance than expected under 
Poisson regression), we can use a negative-binomial regression, however, the effect of 
group assignment should be easier to interpret when using the Poisson regression. All of 
the inferences from these models will be made after adjusting for possible confounders. 
Timeline and resources 
The study will be completed three years after initiation. A principal investigator will 
manage and work with study coordinators in each medical center. Study coordinators will 
be required to collect information, and provide the equipment necessary depending on 
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facility. Assuming a patient was diagnosed at 24 weeks and was recommended to check 
her capillary glucose levels four times a day until 40 weeks of gestation, she would 
require 448 test strips, or 3 purchases of 150 test strips. She would need only 336 if she 
was diagnosed at 28 weeks, which approximates to 3 purchases of 150 test strips as well. 
Therefore, if we are to obtain an iGlucose meter with 150 test strips and purchase 300 test 
strips for the remainder of the pregnancy, the total cost approaches $137.20 per patient at 
co-pay pricing.123 The price of a standard glucose meter ranges from $10-40, and cost of 
test strips vary widely depending on manufacturer and storehouse, and is dependent on 
the Insurance. The expected price range for the control group per patient is between 
$100.00 and $200.00.  The cost of a principal investigator and a minimum of 5 research 
coordinators will span from $300,000 per year to $400,000, with an additional $80,000 
for a statistician. 
Institutional Review Board 
This study protocol will be submitted to the IRB for expedited review under 45 CFR 
46.110 criteria. This study will involve the minimally invasive collection of patient 
records along with patient identification in order to ask patient specific questions 
important for study outcomes. Additionally, information on minors will not be collected 
in this study. It is low risk to the study population, and does not require personal patient 
information.   
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CONCLUSION 
Discussion 
 This study has significant limitations. First, the study does not address the 
cofounders of diet and exercise. GDM can be treated with other methods besides 
controlling with medication. Research has shown that exercise and diet are important 
components in the treatment of diabetes mellitus. Lifestyle intervention is the first line 
treatment in GDM, and in most cases, it is enough to control hyperglycemia in pregnant 
women. Second, this study requires a large sample group of patients diagnosed with 
gestational diabetes that meet the inclusion criteria. Also, this study does not evaluate 
patient satisfaction, which could indicate compliance in the future. Finally, the recruited 
participants will likely be from the Northeast region of the United States. Although the 
study is located in Boston, where there will be a varied population, there is still a risk of 
having a population that lacks diversity.  
 This study has considerable strengths as well. The additional cost of the glucose 
meter and strips is approximately $137.20 per patient, amounting to $27,440 for a 
maximum of 200 subjects in the intervention group. This makes the study feasible. The 
estimated number of pregnancies in the United States in 2009 was 6.369 million. 127 If we 
use this number and estimate that 9% of these pregnancies have GDM, we would have 
approximately Ho3,210 pregnancies in the US with GDM at a given year. If the number 
of prenatal visits is reduced to at least 50% using telemedicine ($137.20 per person adds 
up to $78 million) with improved glycemic control, the cost savings would be 
approximately $200 million.  
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Summary 
GDM is the development of insulin sensitivity during pregnancy. The risks of GDM are 
not only detrimental to the mother, but can affect the fetus during pregnancy and after 
birth. It takes a multidisciplinary team to treat patients and to reduce the risks and prevent 
postnatal complications. To diligently monitor glycemic levels, close follow up is 
recommended, but this can bring major inconvenience to the mother and a heavy burden 
on the clinical schedule. The former is particularly important if the mother has other 
children, works full time, or commuting takes a long time. Telemedicine allows 
immediate assessment of glycemic levels by the providers and instant communication 
with the patient if required.   
  The proposed study will evaluate glycemic levels between two groups. One 
group will follow the traditional treatment of GDM, while the other group will be given a 
glucose meter with ability to transmit information to a safe portal and be treated 
accordingly. The study will also observe the impact of wireless glucose meters on the 
frequency of prenatal visits.   
Clinical and/or public health significance 
While not observed in this study, research has shown that the majority of patients are 
satisfied with telemedicine incorporated into their treatment of diabetes.  If the goals of 
this study are met, patients will benefit from less frequent trips to the doctor’s office and 
receive adequate treatment instantaneously without having to wait for their next prenatal 
visit. 
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Patients with GDM may consider it a temporary disease that does not require 
close observation and management. However, the impact can be life changing to the 
fetus. If by making close management of GDM more feasible using telemedicine, 
benefits may not only be seen in individuals but also in the general cost of this disorder.  
Ultimately, this can reduce the complications associated with GDM and the financial 
burden it conveys.   
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